Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer's disease

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 3, 2012, Pages 529-534

  Zengi, Ouzhan ^a   Karakas, Alpaslan ^a   Ergun, Ufuk ^a   Senes, Mehmet ^a   Inan, Levent ^a   Yucel, Dogan ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

8 hydroxy 2 deoxyguanosine (8 OhdG); Alzheimer's disease; DNA damage; oxidative stress; paraoxonase

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; URINE LEVEL;

AGED; ALZHEIMER DISEASE; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; OXIDATIVE STRESS; ROC CURVE;

EID: 84860451153     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.792     Document Type: Article

References (38)

1. Diamandis M, Diamandis EP, McLaurin JA, Holtzman DM, Schmitt GS, Quirion R. Alzheimer disease: advances in pathogenesis, diagnosis, and therapy. Clin Chem 2011;57:664-9.
2. Harvey J. Leptin: the missing link in Alzheimer disease ? Clin Chem 2010 56 696-7.
3. Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. Age, Alzheimer disease, and brain structure. Neurology 2009;73: 1899-905.
4. Dartigues JF, Feart C. Risk factors for Alzheimer disease: aging beyond age ? Neurology 2011 77 206-7.
5. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-9S. (Pubitemid 30061247)
6. Butterfi eld DA, Lange ML, Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzeheimer's disease. Biochim Biophys Acta 2010;1801:924-9.
7. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002;59:794-8. (Pubitemid 34517762)
8. Bagnyukova TV, Powell CL, Pavliv O, Tryndyak VP, Pogribny IP. Induction of oxidative stress and DNA damage in rat brain by a folate/methyl-defi cient diet. Brain Res 2008;1237:44-51.
9. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-20- deoxyguanosine as a biomarker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA 1989;86:9697-701. (Pubitemid 20030700)
10. Garre-Olmo J, Flaque M, Gich J, Pulido TO, Turbau J, Vallmajo N, et al. A clinical registry of dementia based on the principle of epidemiological surveillance. BMC Neurology 2009;9:5.
11. Mielke MM, Zandi PP, Ogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64:689-95.
12. Sambamurti K, Granholm AC, Kindy MS, Bhat NR, Greig NH, Lahiri DK, et al. Cholesterol and Alzheimer's disease: Clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 2005;5:517-28. (Pubitemid 39004426)
13. Reitz C, Tang M-X, Schupf N, Manly J, Mayeux R, Luchsinger JA. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 2010;67:1491-7.
14. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
16. Folstein MF, Folstein SE, McHugh PR. " Mini-mental state " . A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
18. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identifi cation of phenotypes by their response to salts. Am J Hum Genet 1983;35:214-27. (Pubitemid 13111118)
19. Kim M-H, Moon H-R, Hong S-H. Determination of urinary 8-hydroxy-2-deoxyguanosine as a DNA damage marker. Am Clin Lab 2001;42-5.
20. Mei S, Xu G, Xing J, Wu C. Method for the analysis of 8-hydroxy-2 -deoxyguanosine in urine by gas chromatography. Anal Sci 2001;17:779-81. (Pubitemid 32612265)
21. Yucel D, Aydogdu S, Cehreli S, Saydam G, Canatan H, Senes M, et al. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem 1998;44:148-54. (Pubitemid 28042480)
22. Yucel D, Senes M, Topkaya BC, Zengi O. Oxidative/nitrosative stress in chronic heart failure: a systematic review. Turk J Biochem 2006;31:86-95.
23. Gotz ME, Freyberger A, Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transm 1990;29:241-9.
24. Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-20-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J Neurol 2010;257:399-404.
25. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 2009;109(Suppl. 1):153-9.
26. Gustaw-Rothenberg K, Lerner A, Bonda DJ, Lee H, Zhu X, Perry G, et al. Biomarkers in Alzheimer's disease: past, present and future. Biomark Med 2010;4:15-26.
27. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 1999;9:133-46. (Pubitemid 29056524)
28. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-51. (Pubitemid 24337634)
29. Te Koppele JM, Lucassen PJ, Sakkee AN, van Asten JG, Ravid R, Swaab DF, et al. 8OHdG levels in brain do not indicate oxidative DNA damage in Alzheimer's disease. Neurobiol Aging 1996;17:819-26. (Pubitemid 27022733)
30. Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 2006;96:825-32.
31. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 1999;72:771-6. (Pubitemid 29055242)
32. Kadioglu E, Sardas S, Aslan S, Isik E, Karakaya AE. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers 2004;9:203-9. (Pubitemid 39255641)
33. Lee SH, Kim I, Chung BC. Increased urinary level of oxidized nucleosides in patients with mild-to-moderate Alzheimer's disease. Clin Biochem 2007;40:936-8. (Pubitemid 47307331)
34. Gackowski D, Rozalski R, Siomek A, Dziaman T, Nicpon K, Klimarczyk M, et al. Oxidative stress and oxidative DNA damage is characteristic for mixed Alzheimer disease/vascular dementia. J Neurol Sci 2008;266:57-62. (Pubitemid 351186523)
35. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 2007;35:2497-504.
36. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002;252:63-7. (Pubitemid 36056678)
37. Erlich PM, Lunetta KL, Cupples LA, Abraham CR, Gren RC, Baldwin CT, et al. Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging 2010; [Epub ahead of print], doi:10.1016/j. neurobiolaging.2010.08.003.
38. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;9533:387-403. (Pubitemid 44108123)